HCA Healthcare, Inc. (HCA)
NYSE: HCA · Real-Time Price · USD
390.46
+0.15 (0.04%)
Aug 13, 2025, 4:00 PM - Market closed
HCA Healthcare Stock Forecast
Stock Price Forecast
According to 13 professional analysts, the 12-month price target for HCA Healthcare stock ranges from a low of $336 to a high of $440. The average analyst price target of $395.54 forecasts a 1.30% increase in the stock price over the next year.
Price Target: $395.54 (+1.30%)
Analyst Consensus: Buy
Analyst Ratings
The average analyst rating for HCA Healthcare stock is "Buy". This means that analysts believe this stock is likely to outperform the market over the next twelve months.
Recommendation Trends
| Rating | Mar '25 | Apr '25 | May '25 | Jun '25 | Jul '25 | Aug '25 |
|---|---|---|---|---|---|---|
| Strong Buy | 4 | 4 | 4 | 4 | 2 | 2 |
| Buy | 7 | 6 | 6 | 6 | 6 | 6 |
| Hold | 4 | 6 | 7 | 6 | 8 | 8 |
| Sell | 1 | 1 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 16 | 17 | 17 | 16 | 16 | 16 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| JP Morgan | JP Morgan | Hold Maintains $360 → $370 | Hold | Maintains | $360 → $370 | -5.24% | Aug 4, 2025 |
| Barclays | Barclays | Buy Maintains $416 → $390 | Buy | Maintains | $416 → $390 | -0.12% | Jul 28, 2025 |
| RBC Capital | RBC Capital | Buy Maintains $404 → $401 | Buy | Maintains | $404 → $401 | +2.70% | Jul 28, 2025 |
| Morgan Stanley | Morgan Stanley | Hold Maintains $410 → $400 | Hold | Maintains | $410 → $400 | +2.44% | Jul 28, 2025 |
| Wolfe Research | Wolfe Research | Buy → Hold Downgrades n/a | Buy → Hold | Downgrades | n/a | n/a | Jul 28, 2025 |
Financial Forecast
Revenue This Year
75.69B
from 70.60B
Increased by 7.20%
Revenue Next Year
79.19B
from 75.69B
Increased by 4.63%
EPS This Year
25.61
from 22.00
Increased by 16.41%
EPS Next Year
28.43
from 25.61
Increased by 11.00%
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.
Revenue Forecast
| Revenue | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 79.6B | 84.8B | 90.1B | ||
| Avg | 75.7B | 79.2B | 83.5B | ||
| Low | 72.8B | 74.9B | 79.0B |
Revenue Growth
| Revenue Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 12.7% | 12.1% | 13.8% | ||
| Avg | 7.2% | 4.6% | 5.4% | ||
| Low | 3.0% | -1.1% | -0.3% |
EPS Forecast
| EPS | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 27.17 | 31.52 | 35.82 | ||
| Avg | 25.61 | 28.43 | 32.17 | ||
| Low | 24.16 | 26.50 | 30.44 |
EPS Growth
| EPS Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 23.5% | 23.1% | 26.0% | ||
| Avg | 16.4% | 11.0% | 13.2% | ||
| Low | 9.8% | 3.5% | 7.1% |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.